Citius Pharmaceuticals (NASDAQ:CTXR) Given Buy Rating at HC Wainwright

Citius Pharmaceuticals (NASDAQ:CTXR)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a research note issued on Monday,Benzinga reports. They presently have a $4.00 price target on the stock.

Other research analysts have also issued research reports about the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Citius Pharmaceuticals in a research note on Friday, March 27th. D. Boral Capital reiterated a “buy” rating and issued a $6.00 price target on shares of Citius Pharmaceuticals in a research note on Wednesday, March 11th. Two analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $5.00.

Citius Pharmaceuticals Stock Performance

CTXR traded down $0.15 on Monday, reaching $0.55. The company had a trading volume of 1,835,554 shares, compared to its average volume of 649,691. Citius Pharmaceuticals has a fifty-two week low of $0.48 and a fifty-two week high of $2.48. The stock has a market cap of $12.22 million, a P/E ratio of -0.22 and a beta of 1.05. The company’s fifty day moving average is $0.79 and its 200 day moving average is $0.91.

Citius Pharmaceuticals (NASDAQ:CTXR) last announced its quarterly earnings results on Friday, May 15th. The company reported ($0.95) EPS for the quarter, missing analysts’ consensus estimates of $0.39 by ($1.34). The company had revenue of $1.67 million for the quarter, compared to analyst estimates of $18.79 million.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. XTX Topco Ltd acquired a new position in shares of Citius Pharmaceuticals during the 2nd quarter worth approximately $32,000. NewEdge Advisors LLC acquired a new position in shares of Citius Pharmaceuticals during the 2nd quarter worth approximately $40,000. Asset Advisory Group Inc. acquired a new position in shares of Citius Pharmaceuticals during the 4th quarter worth approximately $46,000. Finally, Heights Capital Management Inc. acquired a new position in shares of Citius Pharmaceuticals during the 4th quarter worth approximately $622,000. Institutional investors and hedge funds own 16.88% of the company’s stock.

About Citius Pharmaceuticals

Citius Pharmaceuticals is a clinical‐stage specialty pharmaceutical company focused on the development and commercialization of critical care products and novel drug delivery systems. Headquartered in Cranford, New Jersey, the company aims to address unmet medical needs in acute care, hospital‐acquired infections and subcutaneous delivery of biologics. Citius operates as a Delaware corporation and trades on the NASDAQ under the symbol CTXR.

One of the company’s leading assets is Mino-Lok, an antibiotic lock solution designed to treat catheter‐related bloodstream infections without catheter removal.